Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Esophageal Cancer | Research article

A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry

Authors: Mohammad Hossein Somi, Roya Dolatkhah, Sepideh Sepahi, Mina Belalzadeh, Shahnaz Naghashi, Mohammad Asghari Jafarabadi

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

The most recent results of Global Cancer Statistics indicated that gastrointestinal cancers, including gastric, colorectal, esophageal, and liver cancers, are among the most commonly diagnosed cancers worldwide. Previous reports from cancer registries in East Azerbaijan have shown that there is a high incidence of gastrointestinal cancer in this region, so we performed a trend analysis to determine the pattern of change over the last decade.

Methods

In total, 12 years of cancer registry data were collected from different sources in East Azerbaijan, and a data quality check was performed to ensure clean data. Using the 2000 World Health Organization standard population, we then generated age-standardized incidence rates (ASRs) for different cancers, and for each year from 1383 to 1394 of the Persian calendar (i.e., 19 March 2004 to 20 March 2015). Annual percent changes (APCs) and Average annual percent changes (AAPCs) in the ASRs for esophageal, gastric, small intestine, colorectal, anal, liver, gallbladder, and pancreatic cancers were calculated using Joinpoint Software (Version 4.5.0.1, June 2017).

Results

An increase in most types of cancer was observed during the study period. The ASR for colorectal cancer increased from 2.9 to 13.6 per 100,000 women (APC, 9.7%) and from 2.2 to 17.8 per 100,000 men (APC, 10.2%). The ASR for gastric cancer showed a slight increasing trend from 10.5 to 13.5 per 100,000 women (APC, 1.3%) and from 3.1 to 29.9 per 100,000 men (APC, 3.2%). However, trend analysis showed a decreasing pattern for the ASR of esophageal cancer in both genders (APC,− 3%), with APCs of − 1.1% in females and − 0.4% in males.

Conclusions

The latest results of the East Azerbaijan Population-Based Cancer Registry indicate that gastrointestinal cancers remain common, with significant increasing trends in their ASRs. Improved screening and early detection are needed in this region.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
2.
Global Burden of Disease Cancer C, Fitzmaurice C, Akinyemiju TF, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–68.CrossRef
3.
Somi MH, Farhang S, Mirinezhad SK, Naghashi S, Seif-Farshad M, Golzari M. Cancer in East Azerbaijan, Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev. 2008;9(2):327–30.PubMed
4.
Somi MH, Golzari M, Farhang S, Naghashi S, Abdollahi L. Gastrointestinal cancer incidence in East Azerbaijan, Iran: update on 5 year incidence and trends. Asian Pac J Cancer Prev. 2014;15(9):3945–9.PubMedCrossRef
5.
Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iran J Public Health. 2018;47(3):309–16.PubMedPubMedCentral
6.
Somi MH, Dolatkhah R, Sepahi S, et al. Cancer incidence in the East Azerbaijan province of Iran in 2015-2016: results of a population-based cancer registry. BMC Public Health. 2018;18(1):1266.PubMedPubMedCentralCrossRef
7.
Roshandel G, Ghanbari-Motlagh A, Partovipour E, et al. Cancer incidence in Iran in 2014: results of the Iranian National Population-based Cancer Registry. Cancer Epidemiol. 2019;61:50–8.PubMedCrossRef
8.
International Classification of Diseases for Oncology. In: Fritz A, Percy C, KJack A, al. E, eds. 3rd Edition ed: WHO Library Cataloguing-in-Publication Data; 2013. Accessed 2016/05/04.
9.
Bray F, Ferlay J, Laversanne M, et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer. 2015;137(9):2060–71.PubMedCrossRef
10.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.PubMedCrossRef
11.
Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576–83.PubMed
12.
Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev. 2005;6(3):359–63.PubMed
13.
Sadjadi A, Malekzadeh R, Derakhshan MH, et al. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer. 2003;107(1):113–8.PubMedCrossRef
14.
Babaei M, Pourfarzi F, Yazdanbod A, et al. Gastric cancer in Ardabil, Iran--a review and update on cancer registry data. Asian Pac J Cancer Prev. 2010;11(3):595–9.PubMed
15.
Islami F, Kamangar F, Aghcheli K, et al. Epidemiologic features of upper gastrointestinal tract cancers in northeastern Iran. Br J Cancer. 2004;90(7):1402–6.PubMedPubMedCentralCrossRef
16.
Zendehdel K, Marzban M, Nahvijou A, Jafari N. Six-fold difference in the stomach cancer mortality rate between northern and southern Iran. Arch Iran Med. 2012;15(12):741–6.PubMed
17.
Mansour-Ghanaei F, Sokhanvar H, Joukar F, et al. Endoscopic findings in a mass screening program for gastric cancer in a high risk region - Guilan province of Iran. Asian Pac J Cancer Prev. 2012;13(4):1407–12.PubMedCrossRef
18.
Haidari M, Nikbakht MR, Pasdar Y, Najaf F. Trend analysis of gastric cancer incidence in Iran and its six geographical areas during 2000-2005. Asian Pac J Cancer Prev. 2012;13(7):3335–41.PubMedCrossRef
19.
Yazdizadeh B, Jarrahi AM, Mortazavi H, Mohagheghi MA, Tahmasebi S, Nahvijo A. Time trends in the occurrence of major GI cancers in Iran. Asian Pac J Cancer Prev. 2005;6(2):130–4.PubMed
20.
Darabi M, Asadi Lari M, Motevalian SA, Motlagh A, Arsang-Jang S, Karimi JM. Trends in gastrointestinal cancer incidence in Iran, 2001-2010: a joinpoint analysis. Epidemiol Health. 2016;38:e2016056.PubMedPubMedCentralCrossRef
21.
Persson C, Jia Y, Pettersson H, Dillner J, Nyren O, Ye W. H. pylori seropositivity before age 40 and subsequent risk of stomach cancer: a glimpse of the true relationship? PloS one. 2011;6(3):e17404.PubMedPubMedCentralCrossRef
22.
Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. The EUROGAST Study Group. Gut. 1993;34(12):1672–1676.
23.
An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST study group. Lancet. 1993;341(8857):1359–62.CrossRef
24.
Sadjadi A, Derakhshan MH, Yazdanbod A, et al. Neglected role of hookah and opium in gastric carcinogenesis: a cohort study on risk factors and attributable fractions. Int J Cancer. 2014;134(1):181–8.PubMedCrossRef
25.
Shakeri R, Malekzadeh R, Etemadi A, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455–61.PubMedCrossRef
26.
Islami F, Nasseri-Moghaddam S, Pourshams A, et al. Determinants of gastroesophageal reflux disease, including hookah smoking and opium use- a cross-sectional analysis of 50,000 individuals. PLoS One. 2014;9(2):e89256.PubMedPubMedCentralCrossRef
27.
Abnet CC, Saadatian-Elahi M, Pourshams A, et al. Reliability and validity of opiate use self-report in a population at high risk for esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomarkers Prev. 2004;13(6):1068–70.PubMed
28.
Malekzadeh MM, Khademi H, Pourshams A, et al. Opium use and risk of mortality from digestive diseases: a prospective cohort study. Am J Gastroenterol. 2013;108(11):1757–65.PubMedPubMedCentralCrossRef
29.
Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–27.CrossRef
30.
Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–48.CrossRef
31.
Rohani-Rasaf M, Abdollahi M, Jazayeri S, Kalantari N, Asadi-Lari M. Correlation of cancer incidence with diet, smoking and socio- economic position across 22 districts of Tehran in 2008. Asian Pac J Cancer Prev. 2013;14(3):1669–76.PubMedCrossRef
32.
Mashhadi M, Zakeri Z, Abdollahinejad M. Cancer incidence in south east of Iran: results of a population-based cancer registry. Shiraz E Med J. 2010;11(3):e20401.
33.
Dolatkhah R, Somi MH, Kermani IA, et al. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC Public Health. 2015;15:997.PubMedPubMedCentralCrossRef
34.
Hosseini SV, Izadpanah A, Yarmohammadi H. Epidemiological changes in colorectal cancer in shiraz, Iran: 1980-2000. ANZ J Surg. 2004;74(7):547–9.PubMedCrossRef
35.
Haghdoost A, Chamani G, Zarei MR, Rad MB, Hashemipour M, Marzaban M. Low incidence of colorectal cancer in Kerman province, Iran. Iran J Cancer Prev. 2011;4(1):33–7.
36.
Sadjadi A, Zahedi MJ, Darvish-Moghadam S, et al. The first population-based cancer survey in Kerman province of Iran. Iran J Public Health. 2007;36(4):26–34.
37.
Donohoe CL, Pidgeon GP, Lysaght J, Reynolds JV. Obesity and gastrointestinal cancer. Br J Surg. 2010;97(5):628–42.PubMedCrossRef
38.
Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr. 2002;5(1A):149–55.PubMedCrossRef
39.
Azizi F, Allahverdian S, Mirmiran P, Rahmani M, Mohammadi F. Dietary factors and body mass index in a group of Iranian adolescents: Tehran lipid and glucose study--2. Int J Vitam Nutr Res. 2001;71(2):123–7.PubMedCrossRef
40.
41.
Hossein Somi M, Mirinezhad K, Farhang S, et al. Gastrointestinal cancer occurrence in East Azarbaijan: a five year study from North Western Iran. Asian Pac J Cancer Prev. 2006;7(2):309–12.PubMed
42.
Mirzaei M, Ghoncheh M, Pournamdar Z, Soheilipour F, Salehiniya H. Incidence and trend of liver Cancer in Iran. J Coll Physicians Surg Pak. 2016;26(4):306–9.PubMed
43.
Hajizadeh N, Baghestani AR, Pourhoseingholi MA, et al. Trend of hepatocellular carcinoma incidence after Bayesian correction for misclassified data in Iranian provinces. World J Hepatol. 2017;9(15):704–10.PubMedPubMedCentralCrossRef
44.
Roshandel G, Sadjadi A, Aarabi M, et al. Cancer incidence in Golestan Province: report of an ongoing population-based cancer registry in Iran between 2004 and 2008. Arch Iran Med. 2012;15(4):196–200.PubMed
45.
Mosavi-Jarrahi A, Mohagheghi MA. Epidemiology of esophageal cancer in the high-risk population of Iran. Asian Pac J Cancer Prev. 2006;7(3):375–80.PubMed
46.
Gholipour M, Islami F, Roshandel G, et al. Esophageal Cancer in Golestan Province, Iran: a review of genetic susceptibility and environmental risk factors. Middle East J Dig Dis. 2016;8(4):249–66.PubMedPubMedCentralCrossRef
47.
Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21(4):322–7.PubMedCrossRef
48.
Nasrollahzadeh D, Kamangar F, Aghcheli K, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer. 2008;98(11):1857–63.PubMedPubMedCentralCrossRef
49.
Shakeri R, Kamangar F, Nasrollahzadeh D, et al. Is opium a real risk factor for esophageal cancer or just a methodological artifact? Hospital and neighborhood controls in case-control studies. PLoS One. 2012;7(3):e32711.PubMedPubMedCentralCrossRef
50.
Shakeri R, Kamangar F, Mohamadnejad M, et al. Opium use, cigarette smoking, and alcohol consumption in relation to pancreatic cancer. Medicine. 2016;95(28):e3922.PubMedPubMedCentralCrossRef
51.
Friesen M, O'Neill IK, Malaveille C, et al. Characterization and identification of 6 mutagens in opium pyrolysates implicated in oesophageal cancer in Iran. Mutat Res. 1985;150(1–2):177–91.PubMedCrossRef
Metadata
Title
A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry
Authors
Mohammad Hossein Somi
Roya Dolatkhah
Sepideh Sepahi
Mina Belalzadeh
Shahnaz Naghashi
Mohammad Asghari Jafarabadi
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6008-3

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Developing a real-time electronic symptom monitoring system for patients after discharge following cancer-related surgery

Research article

Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy

Technical Advance

Protein interaction disruption in cancer

Research article

Cancer stigma and cancer screening attendance: a population based survey in England

Research article

Preoperative maximum standardized uptake value and carbohydrate antigen 19–9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma

Research article

Clinical significance of neutrophil-to-lymphocyte ratio as a predictor of lymph node metastasis in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits